Optimer (OPTR) Announces Add-on Payment From Medicare & Medicaid Services for its DIFICID
- Allergan (AGN), Valeant (VRX), Pershing Square Enter Litigation Settlement; Special Meeting Date Set
- Unusual 11 Mid-Day Movers 9/16: (SINO) (SCOK) (VIMC) Higher; (VHC) (AT) (COOL) Lower
- Hertz Global (HTZ), Icahn Reach Agreement Over Director Appointments
- Washington Prime (WPG) to Acquire Glimcher Realty Trust (GRT) for $14.20/Share
- Apple's (AAPL) New iPhone 6/6+ May Not Hit China Until Early 2015
Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that the Centers for Medicare & Medicaid Services (CMS) has granted a new technology add-on payment (NTAP) for DIFICID tablets administered in the inpatient setting to treat Clostridium difficile-associated diarrhea (CDAD). Introduced in 2001, the CMS NTAP program is designed to support timely access of innovative therapies used to treat Medicare beneficiaries in the inpatient setting. The NTAP program is only available to new technologies demonstrating a substantial clinical improvement and meeting specific cost thresholds. The NTAP payment will provide hospitals with a payment, in addition to the standard-of-care DRG reimbursement, of up to 50% of the cost of DIFICID for a period of two to three years, effective in the fiscal year starting on October 1, 2012. For 2013, CMS has assigned a maximum payment of $868.00. The NTAP payment is available to hospitals only for individual patient cases that are more costly than the average DRG charges.
You May Also Be Interested In
- Nektar Therapeutics (NKTR) Wins FDA Approval of Movanik
- OncoGenex Pharma (OGXI) Completes Enrollment in AFFINITY Phase 3
- Amarin Corp plc (AMRN) Affirms Commitment to Completion of REDUCE-IT
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!